OTCMKTS:GSGTF GenSight Biologics (GSGTF) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free GSGTF Stock Alerts $0.45 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.4550-Day Range$0.45▼$0.4752-Week Range$0.00▼$0.80VolumeN/AAverage Volume583 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get GenSight Biologics alerts: Email Address Ad Chaikin Analytics“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.Just click here. About GenSight Biologics Stock (OTCMKTS:GSGTF)GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.Read More GSGTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GSGTF Stock News HeadlinesApril 18, 2024 | businesswire.comGenSight Biologics Announces the Filing of its 2023 Universal Registration DocumentApril 4, 2024 | businesswire.comGenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business UpdateApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)March 22, 2024 | finance.yahoo.comGenSight Biologics Reports Full Year 2023 Consolidated Financial ResultsMarch 20, 2024 | finance.yahoo.comGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time AdministrationMarch 6, 2024 | finance.yahoo.comGenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024February 16, 2024 | finance.yahoo.comGenSight Biologics S.A. (GSGTF)February 8, 2024 | finance.yahoo.comGenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights CapitalApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)January 25, 2024 | finance.yahoo.comGenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business UpdateJanuary 16, 2024 | finance.yahoo.comLaurence Rodriguez, Appointed CEO of GenSight Biologics in December 2023, Joins the Company’s Board of DirectorsDecember 27, 2023 | finance.yahoo.comGenSight Biologics Provides Business and Financial UpdateDecember 22, 2023 | finance.yahoo.comGenSight Biologics appoints Laurence Rodriguez as Chief Executive OfficerNovember 23, 2023 | seekingalpha.comBiologicsNovember 22, 2023 | morningstar.comGensight Biologics SA SIGHTNovember 15, 2023 | finance.yahoo.comGenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 millionOctober 26, 2023 | finance.yahoo.comGenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business UpdateSeptember 27, 2023 | finance.yahoo.comGenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®September 18, 2023 | finance.yahoo.comGenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP BatchSeptember 15, 2023 | finance.yahoo.comGenSight Biologics Reports Interim Financial Results for the First Half of 2023July 30, 2023 | nbcnews.comUFO whistleblower alleges 'non-human' biologics found at crash sitesJuly 20, 2023 | finance.yahoo.comGenSight Biologics Provides Financial and Operational UpdateMay 10, 2023 | finance.yahoo.comGenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023May 2, 2023 | wsj.comGenSight Biologics S.A.May 1, 2023 | finance.yahoo.comGenSight Biologics Announces the Re-approval of its Full Year 2022 Consolidated Financial StatementsApril 20, 2023 | finance.yahoo.comGenSight Biologics Withdraws its EMA Application for LUMEVOQ®April 20, 2023 | finance.yahoo.comGenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business UpdateSee More Headlines Receive GSGTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenSight Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GSGTF CUSIPN/A CIKN/A Webwww.gensight-biologics.com Phone(317) 621-7220FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Laurence RodriguezCEO & DirectorDr. Jose-Alain Sahel M.D.Ph.D., Scientific Founder, Vice Chairman of Scientific Advisory Board & Board ObserverProf. Botond RoskaScientific Founder & Chairman of Scientific Advisory BoardDr. Luk H. Vandenberghe M.D.Ph.D., Scientific Founder & Member of Scientific Advisory BoardDr. Serge PicaudScientific Founder & Member of Scientific Advisory BoardDr. Constance L. Cepko Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Ivan Tortet (Age 58)Interim Chief Financial Officer Mr. Scott JeffersChief Technical OfficerDr. Barrett Katz CMO (Age 73)M.B.A., M.D., Consultant Dr. Magali Taiël M.D.Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors GSGTF Stock Analysis - Frequently Asked Questions How have GSGTF shares performed in 2024? GenSight Biologics' stock was trading at $0.47 at the beginning of the year. Since then, GSGTF stock has decreased by 4.3% and is now trading at $0.45. View the best growth stocks for 2024 here. How do I buy shares of GenSight Biologics? Shares of GSGTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GSGTF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenSight Biologics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
